Fresenius appoints Dennis Hofmann as Head of Corporate Communications

“I would like to express my sincere gratitude to Matthias Link for his many years of very successful commitment and service to our company and wish him all the best for his future endeavors. Equally, I am very much looking forward to working with Dennis Hofmann. In Dennis, we gain a proven communications expert with a good understanding of people and issues relevant to the company. His diverse communications experience across industries and surrounding the implementation of transformation processes will further strengthen Fresenius’ positioning as a leading healthcare company and make him an asset to our management team”, said Michael Sen, CEO of Fresenius.

“Now more than ever, communication plays a crucial role on the path to #FutureFresenius. I am honored to lead the communications department of such a great company”, Hofmann said. “Every day, more than 300,000 employees worldwide contribute to improving the quality of life of millions of people. It’s a privilege to be part of Fresenius’ mission and I will work with my team to ensure we  deliver strong corporate communications support that drives business growth and cultural change.”

Dennis Hofmann took up his position as Head of Global Communications at Fresenius Kabi in September 2022. Previously, he spent several years in senior positions within the communications, marketing, and investor relations fields. Most recently he served as Senior Vice President for Corporate Communications & Investor Relations at Leoni AG in Nuremberg. Prior to that, he spent approximately 18 years at Siemens AG where, in his final four years, he held the position of Corporate Senior Vice President for Global Internal and External Communications.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.